tradingkey.logo
tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
3.270USD
-0.030-0.91%
終値 12/26, 16:00ET15分遅れの株価
473.23M時価総額
損失額直近12ヶ月PER

Maravai LifeSciences Holdings Inc

3.270
-0.030-0.91%

詳細情報 Maravai LifeSciences Holdings Inc 企業名

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Maravai LifeSciences Holdings Incの企業情報

企業コードMRVI
会社名Maravai LifeSciences Holdings Inc
上場日Nov 20, 2020
最高経営責任者「CEO」Brust (Bernd)
従業員数570
証券種類Ordinary Share
決算期末Nov 20
本社所在地10770 Wateridge Circle Suite 200
都市SAN DIEGO
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号92121
電話番号18585460004
ウェブサイトhttps://www.maravai.com/
企業コードMRVI
上場日Nov 20, 2020
最高経営責任者「CEO」Brust (Bernd)

Maravai LifeSciences Holdings Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
339.36K
+1.28%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
175.77K
+131.98%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
+182.23%
Dr. John A. Deford, Ph.D.
Dr. John A. Deford, Ph.D.
Independent Director
Independent Director
--
--
Mr. Sean L. Cunningham
Mr. Sean L. Cunningham
Director
Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
339.36K
+1.28%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
175.77K
+131.98%

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
North America
30.64M
64.64%
Europe, the Middle East and Africa
8.39M
17.71%
Asia Pacific
8.16M
17.21%
Latin and Central America
327.00K
0.69%
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
GTCR Golder Rauner, LLC
13.89%
12 West Capital Management, L.P.
8.63%
Hudson View Capital LLC
6.17%
Braidwell LP
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
他の
60.24%
株主統計
株主統計
比率
GTCR Golder Rauner, LLC
13.89%
12 West Capital Management, L.P.
8.63%
Hudson View Capital LLC
6.17%
Braidwell LP
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
他の
60.24%
種類
株主統計
比率
Investment Advisor
29.58%
Hedge Fund
25.00%
Investment Advisor/Hedge Fund
17.45%
Private Equity
13.89%
Individual Investor
6.63%
Corporation
6.17%
Research Firm
4.39%
Pension Fund
0.20%
Bank and Trust
0.14%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
518
128.65M
88.93%
-44.43M
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
2023Q3
641
137.53M
104.23%
-17.92M
2023Q2
646
129.68M
98.32%
-22.48M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
GTCR Golder Rauner, LLC
20.15M
13.93%
--
--
Jun 30, 2025
12 West Capital Management, L.P.
12.52M
8.65%
--
--
Jun 30, 2025
Hudson View Capital LLC
6.87M
4.75%
+6.87M
--
May 21, 2025
Braidwell LP
8.35M
5.77%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
5.81%
+52.73K
+0.63%
Jun 30, 2025
The Vanguard Group, Inc.
9.38M
6.48%
-2.26M
-19.38%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
2.64M
1.83%
+2.64M
--
Jun 30, 2025
Mackenzie Investments
6.07M
4.2%
-44.32K
-0.72%
Jun 30, 2025
Renaissance Technologies LLC
4.19M
2.89%
+75.50K
+1.84%
Jun 30, 2025
Mirabella Financial Services LLP
3.75M
2.59%
+10.05K
+0.27%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
Global X Genomics & Biotechnology ETF
0.41%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
詳細を見る
Global X Genomics & Biotechnology ETF
比率0.41%
Invesco Nasdaq Biotechnology ETF
比率0.05%
ProShares Ultra Nasdaq Biotechnology
比率0.04%
iShares Biotechnology ETF
比率0.03%
Invesco RAFI US 1500 Small-Mid ETF
比率0.03%
iShares Russell 2000 Value ETF
比率0.02%
Schwab U.S. Small-Cap ETF
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
ProShares Hedge Replication ETF
比率0.01%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Maravai LifeSciences Holdings Incの上位5名の株主は誰ですか?

Maravai LifeSciences Holdings Incの上位5名の株主は以下のとおりです。
GTCR Golder Rauner, LLCは20.15M株を保有しており、これは全体の13.93%に相当します。
12 West Capital Management, L.P.は12.52M株を保有しており、これは全体の8.65%に相当します。
Hudson View Capital LLCは6.87M株を保有しており、これは全体の4.75%に相当します。
Braidwell LPは8.35M株を保有しており、これは全体の5.77%に相当します。
BlackRock Institutional Trust Company, N.A.は8.41M株を保有しており、これは全体の5.81%に相当します。

Maravai LifeSciences Holdings Incの株主タイプ上位3種は何ですか?

Maravai LifeSciences Holdings Incの株主タイプ上位3種は、
GTCR Golder Rauner, LLC
12 West Capital Management, L.P.
Hudson View Capital LLC

Maravai LifeSciences Holdings Inc(MRVI)の株式を保有している機関の数はいくつですか?

2025Q3時点で、Maravai LifeSciences Holdings Incの株式を保有している機関は518社あり、保有株式の総市場価値は約128.65Mで、全体の88.93%を占めています。2025Q2と比較して、機関の持ち株は-11.28%増加しています。

Maravai LifeSciences Holdings Incの最大の収益源は何ですか?

FY2025Q2において、--部門がMaravai LifeSciences Holdings Incにとって最大の収益を生み出しており、その金額は--で、全収益の--%を占めています。
KeyAI